Posts Tagged ‘pharmaceutical industry’

Anticompetitive Pricing for Diabetes and Obesity Drugs

April 4, 2024 — We have much to learn from a recent crisis of escalating insulin prices. This is the bottom line of a new paper in Diabetes Care. In short, multifaceted public policy action eased that crisis. So it has important implications for issues with anticompetitive pricing of diabetes and obesity medicines broadly. Anticompetitive Pricing Practices Authors Kathryn […]

Will Policy Makers or Market Forces Lower GLP-1 Costs First?

March 28, 2024 — A new economic analysis in JAMA Network Open brings unsurprising news: manufacturing costs for GLP-1 agonists are a tiny fraction of the price for these important medicines. This is always the case for innovative prescription drugs that must recover billions of dollars of development costs in order to be profitable. The response from policy makers […]

Lining Up at Amazon and LillyDirect for Obesity Medicines

March 18, 2024 — Hear that rumble? Nope, it not the latest SpaceX launch. It is the roar of growing demand for obesity care in the U.S. Two pieces of news in the last week remind us of how steep the upward line of growth in obesity treatment is right now. To help it scale up their reach to […]

FDA Approves Resmetirom: First Ever for MASH with Fibrosis

March 16, 2024 — Firsts are worth celebrating. In this case, the cause for celebration is especially great. MASH or metabolic steatohepatitis is a disease that is growing dramatically more common and more harmful to the health of the population. Late this week, FDA approved resmetirom to be the first ever treatment for MASH with fibrosis. Note that the […]

Scarcity, Greed, and Drug Pricing in an Election Year

March 10, 2024 — For many of us, it’s just too painful to think about. But a rerun of the 2020 presidential election is coming and drug pricing is likely to be a big talking point for both of the major candidates. President Biden is talking about corporate greed while former President Trump is talking about reviving an executive […]

Indication for Heart Health Marks a New Era in Obesity Treatment

March 9, 2024 — It’s official. FDA now says that semaglutide, in doses used to treat obesity, can prevent heart attacks, strokes, and deaths in persons with cardiovascular disease and overweight or obesity. This is nothing short of the dawn of a new era in obesity treatment. FDA Division Director John Sharretts said it clearly: “This patient population has […]

More News Points to Explosive Growth for GLP-1 Medicines

February 7, 2024 — Let’s be clear from the start. Hype about “weight loss” drugs is exquisitely unhelpful. This is because weight loss is only an acute effect of new medicines that act on GLP-1 receptors and related pathways that influence obesity. The real need for these medicines is to control a whole range of chronic health problems that […]

Fix the Blind Spot in Drug Trials Says Every Major Obesity Group

November 29, 2023 — It is time to translate words into action and fix the blind spot in drug trials and labeling for people with obesity. Every major obesity group in the U.S. issued this united call to action on Tuesday. This includes the ASMBS, Obesity Action Coalition, Obesity Medicine, Obesity Society, and STOP Obesity Alliance. It comes as […]

Compounding, Biosimilars, Generics, and the Semaglutide Supply

October 30, 2023 — It leaves our heads spinning. Normal healthcare systems cannot keep up with the demand for a breakthrough in obesity treatment. The company, Novo Nordisk, which developed semaglutide for obesity treatment, has invested billions and now is reaping many billions of dollars in sales. But despite more than a decade of preparation, they can’t keep up. […]

KFF Survey: Curious About Obesity Meds, Daunted by Obesity

August 6, 2023 — On Friday, the Kaiser Family Foundation (KFF) released remarkably detailed results from a survey of public awareness and beliefs about new obesity medicines. It offers much for us to think about. But at the very top line it puts some solid numbers on a basic fact about the public response to breakthrough medicines for obesity. […]